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Thomas Arendt1*, Martina K Brückner1, Markus Morawski1, Carsten Jäger1 and Hermann-Josef Gertz2Abstract
Alzheimer’s disease (AD) is a degenerative disorder where the distribution of pathology throughout the brain is not
random but follows a predictive pattern used for pathological staging. While the involvement of defined functional
systems is fairly well established for more advanced stages, the initial sites of degeneration are still ill defined. The
prevailing concept suggests an origin within the transentorhinal and entorhinal cortex (EC) from where pathology
spreads to other areas. Still, this concept has been challenged recently suggesting a potential origin of degeneration in
nonthalamic subcortical nuclei giving rise to cortical innervation such as locus coeruleus (LC) and nucleus basalis of
Meynert (NbM). To contribute to the identification of the early site of degeneration, here, we address the question
whether cortical or subcortical degeneration occurs more early and develops more quickly during progression of AD.
To this end, we stereologically assessed neurone counts in the NbM, LC and EC layer-II in the same AD patients ranging
from preclinical stages to severe dementia. In all three areas, neurone loss becomes detectable already at preclinical
stages and is clearly manifest at prodromal AD/MCI. At more advanced AD, cell loss is most pronounced in the NbM >
LC > layer-II EC. During early AD, however, the extent of cell loss is fairly balanced between all three areas without clear
indications for a preference of one area. We can thus not rule out that there is more than one way of spreading from
its site of origin or that degeneration even occurs independently at several sites in parallel.
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Alzheimer’s disease (AD) is a slowly progressing neuro-
degenerative disorder associated with a progressive loss
of cognitive function eventually leading to dementia.
The underlying pathological process is characterized by
neuronal cell death, accompanied by typical neuropatho-
logical hallmarks, i.e. extracellular deposits of Aß-peptide
and intracellular formation of fibrillar aggregates of abnor-
mally phosphorylated tau protein. Depositions of both ag-
gregated Aß and tau are not distributed randomly
throughout the brain but rather follow a highly predictive
pattern of progression which provides the basis for neuro-
pathological staging of the disease [1,2].
Recent evidence [3] indicates that the pathological
process begins years if not decades before clinical symp-
toms occur. This long “preclinical” phase of AD is of
pivotal importance to understand the origin of the* Correspondence: aret@medizin.uni-leipzig.de
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unless otherwise stated.disease and may provide a promising time window for
potential therapeutic intervention. Exact knowledge on
the pathological process occurring during this preclinical
phase, however, is difficult to obtain. In a recent system-
atic survey on more than 2300 nonselected autoptic
cases, Braak et al. [4] observed deposits of phospho-tau,
immunoreactive for the antibody AT8 already in the first
decades of life. Of note, formation of abnormally phos-
phorylated tau frequently was observed in individuals
under 30 years of age and, in addition to the transen-
torhinal cortex, first became detectable in subcortical
nuclei with projection to the cerebral cortex, i.e. locus
coeruleus (LC) and nucleus basalis of Meynert (NbM).
It remains unclear at present, however, whether these
changes referred to as “pretangles” which represents
non-aggregated soluble tau in a hyperphosphorylated
form will eventually convert into insoluble PHF-tau.
Only a subset of subjects with these changes early in life
seem to progress to AD [5]. Even a PHF-like pattern of
tau hyperphosphorylation is not necessarily associated
with a conversion into aggregated PHF-tau and canThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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bernation [6], hypothermia and anesthesia [7] where it is
fully reversible. While the pathophysiological signifi-
cance of so-called “pretangle” tau is not entirely clear, its
simultaneous occurrence at both cortical areas and sub-
cortical projection nuclei again brings the old question
into new focus of whether degeneration in AD is of sub-
cortical or cortical origin [8-11].
In the mid-late seventies of the 20th century, reduc-
tions in the activity of choline acetyltransferase, the bio-
synthetic enzyme for acetylcholine, [12-14] as well as in
the levels of noradrenaline and the activity of its syn-
thetic enzyme dopamine-ß-hydroxylase [15-17] were de-
scribed in the cerebral cortex of AD patients. As the
human cerebral cortex does not contain cholinergic or
noradrenergic neurons, these transmitter deficiencies
were correctly attributed to a dysfunction in the ascend-
ing cholinergic and noradrenergic innervation of the
cortex arising in the basal nucleus of Meynert [18,19]
and locus coeruleus, respectively. A corresponding loss
of neurons in the NbM was first reported in 1982 [20]
and rapidly confirmed by others [9,21-24]. Systematic
studies clearly indicated that loss of cholinergic NbM
neurons occurs early during the course of AD [25,26]
and very unlikely is an event secondary to cortical de-
generation [10]. The critical role of cholinergic dysfunc-
tion in early AD is clearly documented by the fact that
pharmacological inhibition of acetylcholinesterase still is
the only treatment available for a modest symptomatic
therapy during early stages of the disease.
In parallel with descriptions on the cholinergic dys-
function in AD, a neurone loss has consistently been re-
ported for the locus coeruleus [22,27-44]. These cells of
the locus coeruleus and nucleus basalis of Meynert share
a non-specialised, isodendritic pattern [25,26,45-48]
which have led to the suggestion that they may represent
a pool of relatively undifferentiated cells with a high sus-
ceptibility to degeneration [47,49]. Formation of cortical
plaques and tangles and cortical dysfunction where, thus
regarded as phenomena secondary to the loss of the as-
cending inputs [8-11,48]. Still, most systematic surveys
on the distribution and progression of neurofibrillary de-
generation over the last 25 years or so have focused the
attention on the cerebral cortex [1,50-55] where the en-
torhinal and transentorhinal cortex appear to be affected
most early. Accordingly, a pathogenetic concept has
been formulated assuming the process of degeneration
starts in the transentorhinal cortex from where it
spreads throughout the brain [56]. Still, more recent
findings on early subcortical “pretangle tau pathology” in
nonthalamic subcortical nuclei innervating the cortex,
including LC and NbM, have again challenged this con-
cept and a potential subcortical origin of neurodegenera-
tion was again acknowledged [56].Until now, only a few studies with a restricted number
of patients have compared neuronal loss as a direct
quantitative measure of degeneration in the NbM and
LC, and to the best of our knowledge there is no study
comparing cell loss in the ascending projection neurons
of the NbM and LC with those in the entorhinal cortex.
Therefore, to contribute to the identification of the early
site of degeneration in AD, here, we address the ques-
tion whether cortical or subcortical degeneration occurs
more early and develops more quickly during progres-
sion of the disease. We have assessed by stereological
methods neurone counts in the NbM, LC and entorhinal
cortex of the same individual autopsy cases covering a
wide spectrum of disease stages from preclinical AD to
severe dementia.
Materials and methods
Patients and healthy controls
Brain tissue of 101 AD patients and 19 healthy controls
dying without any history of neurological or psychiatric
illness was used. The diagnosis of AD was made on the
basis of both clinical and neuropathological evidence ac-
cording to the criteria of the International Working
Group (IWG) for New Research Criteria for the diagno-
sis of AD [57,58] in the revision of 2014 (IWG-2) [59],
the NIA-AA diagnostic criteria in the revision of 2011
[3,60-62] and the NIA-AA guidelines for the neuro-
pathological assessment of AD [63,64]. Only cases with
typical AD according to IWG-2 criteria were included.
Cases with history of stroke as well as other central ner-
vous system disorders such as tumors, inflammation,
Lewy body disease or frontotemporal dementia and pre-
mortem hypoxia related to agonal states were excluded
from the present study. Cases with substantial micro-
vascular pathology such as cortical microinfarcts, deep
white matter and periventricular demyelination, silent la-
cunar infarcts and extensive leukoaraiosis as well as
cases with argyrophilic grain disease were also excluded.
All cases underwent neuropsychological assessment
within the last 6 months prior to their death. Clinical
Dementia Rating (CDR) scale scoring was based on
neuropsychological testing (CERAD) [65], MMSE [66]
and rating scales [67]. CDR scale score was used to as-
sign cognitive function to five levels defined as no mem-
ory loss (CDR 0), questionable dementia (CDR 0.5), mild
dementia (CDR 1), moderate dementia (CDR 2), and se-
vere dementia (CDR 3) [68]. All cases were neuropatho-
logically assessed for NFT stage according to Braak and
Braak [1], and Braak et al. [50], for Aß/amyloid plaque
score according to Thal et al. [2] and for neuritic plaque
score according to CERAD [69]. NFTs and Aß/amyloid
plaques were detected by immunocytochemical labeling
of phospho-tau (anti-human PHF-tau monoclonal anti-
body AT8; Thermo Scientific) and Aß (beta amyloid
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Severity of AD pathology was scored following the
consensus guidelines for the neuropathologic evalu-
ation of Alzheimer’s Disease according to Hyman et al.
[63] and Montine et al. [64]. Case recruitment, autopsy
and data handling have been performed in accordance
with the ethical standards as laid down in the 1964
Declaration of Helsinki and its later amendments as
well as with the convention of the Council of Europe
on Human Rights and Biomedicine and had been ap-
proved by the responsible Ethics Committee of Leipzig
University.
Based on neuropsychological assessment (CDR) and
neuropathological examination [63,64], cases were allo-
cated to one of the following six groups.
1. Controls. Individuals with a complete absence of
clinical symptoms of AD (CDR = 0) and of AD pathology
(ABC-score=“Not”) were considered as controls.
2. Preclinical AD. Individuals with a complete absence
of clinical symptoms of AD (CDR = 0) and the presence
of initial AD pathology, scored as ABC-score=“Low”
were considered as preclinical cases of AD (asymptom-
atic at risk according to IWG-2; preclinical AD stages 1
and 2 according to NIA-AA).
3. Prodromal AD/MCI. Individuals with early cognitive
symptoms not reaching severity of dementia (CDR = 0.5)
in combination with the presence of AD pathology,
reaching an ABC-score of “Low” or “Intermediate” were
considered as prodromal AD according to IWG-2 and
AD-MCI according to NIA-AA criteria.
4–6. AD dementia. Individuals with some form of
dementia (CDR between 1 and 3) in combination with a
ABC-score of “Intermediate” or “High” and the absence
of exclusion criteria (see above) were considered typical
AD dementia according to IWG-2 and and NIA-AA
criteria and indexed according to their CDR-score as
mild AD (Group 4), moderate AD (Group 5) and severe
AD (Group 6).
Tissue processing and stereological analysis
Brains were immersed in 4% formaldehyde in phosphate
buffer (0.1 M; pH 7.4) for one month. Tissue blocks con-
taining the entorhinal cortex, basal nucleus of Meynert
complex and the locus coeruleus were immersed in 30%
sucrose for cryoprotection and cut in the coronal plane
on a freezing microtome at a microtome setting of
30 μm. Every 10th section was collected for sampling.
Total neurone number in the NbM, LC and Layer II
of the entorhinal cortex was determined by the unbiased
stereological method of the optical fractionator [70].
Cholinergic neurons of the nucleus basalis Meynert
complex, consisting of the medial septal nucleus (Ch1),
nucleus of the vertical limb of the diagonal band (Ch2)and substantia innominate (Ch4) were identified by im-
munocytochemical detection of choline acetyltransferase
[26,71] using a goat anti-choline acetyltransferase poly-
clonal antibody (AB 144P Chemicon) as described [72].
Boundaries of the NbM complex were identified based
on a previous three-dimensional reconstruction com-
prising the subpopulations of Ch1, Ch2, Ch4am, Ch4al,
Ch4i and Ch4p [9,73]. Neurons were sampled over the
entire length of the NbM complex extending from the
septum (Ch1) to its most posterior parts (Ch4p) at the
premammillary level posterior to the ansa peduncularis.
Neurons of the locus coeruleus were identified by the
presence of neuromelanin [74,75]. In the present study,
the term locus coeruleus (LC) refers to both the nucleus
coeruleus and nucleus subcoeruleus. For outlining layer
II of the entorhinal cortex, we followed the criteria of
Amaral and Insausti [76] and Insausti et al. [77]. The en-
torhinal cortex was sampled throughout its entire length
extending from 2 to 3 mm behind the frontotemporal
junction (limen insulae) to the rostral pole of the lateral
geniculate nucleus.
Neuronal counts were performed on Nissl-counterstained
sections on a Zeiss Axiophot, equipped with a motorized
stage (Märzhäuser, Wetzlar, Germany), a Ludl MAC 5000
(LEP, Hawthorne, NY, USA) and a digital camera CX 9000
(MicroBrightField, Williston, VT, USA). The anatomical
boundaries of the considered region were outlined
using a 5x lens and the reference volume for each
structure was determined from these areas encircled on
each section averaged over the entire length of the
structure (principle of Cavalieri). The disector was
150x150μm wide and 10 μm in height. Post-processing
shrinkage of tissue resulted in a final section thickness
of 18 +/− 2 μm, which permitted a consistent sampling
of 10 μm with the dissector and the use of guard zones
of at least 3 μm on either side of the section. On aver-
age, 300 – 600 profiles were counted with a 20x lens in
each case and region.
The intra individual coefficient of error (CE) for the
individual estimates of cell numbers ranged from 0.01 to
0.08 with an overall average of 0.046. The inter-
individual coefficient of variation (CV) within each of
the six different groups ranged from 0.0081 to 0.372.
The ratio CE2/CV2, thus, ranged from 0.005 to 0.25, in-
dicating that the precision obtained with the sampling
scheme was sufficient for optimal sampling [70].
To make the changes in neurone number comparable
obtained for the three different regions at different
stages of AD, we calculated the effect size “d” of cell loss
compared to the appropriate control group according to
Hedges and Olkin [78]. Effect size “d” is defined as the
mean of controls (indexed as “1”) minus the mean of AD
(indexed as “2”), divided by the pooled standard devi-
ation “s*” (n: sample size; s: standard deviation).
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Results
Both cortical and subcortical cell loss can be detected
already at prodromal stages of Alzheimer’s disease
In the normal aged brain (mean age 81.3 +/− 4.4 years;
see Table 1), we determined the mean number of neu-
rons in the NbM, in the LC and in Layer II of the en-
torhinal cortex at 168,834+/−25,573, 17,487+/−2,736
and 677,685+/−88,072, respectively. As can be seen in
Figure 1, there was, however, a rather large inter-
individual variety and neuron count varied from 125,734
to 215,827 in the NbM (CV = 0.15), from 13,371 to 22,712
in the LC (CV = 0.15) and from 512,914 to 810,211 in the
entorhinal cortex, layer II (CV = 0.13).
In AD, there occurred a progressive loss of neurons
in all three areas which paralleled the progression of
the disease. Also, there was a large individual range in
neurone count for each group. At preclinical stages of
AD, neurone count in all three areas tended to be re-
duced. Cell loss, however, was insignificantly small
(NbM: 4.3+/−2.6%; LC: 3.0+/−2.5%; entorhinal cortex,
layer II: 3.1+/−2.6%). Still, at stages of prodromal AD/
MCI, neurone loss was significant at a level of p < 0,05
in all three areas, amounting to 14.36+/−4.0% in the
NBM, 13.33+/−2.7% in the LC and 12.45+/−2.6% in the
entorhinal cortex, layer II. AT8 immunoreactive PHF-
tau could be detected in all three areas already at pre-
clinical as well as at all subsequent stages (Table 1).
Neurone loss further progressed in the groups of mild
dementia (NbM: 33.48+/−3.6%; LC: 33.5+/−3.3%, ento-
rhinal cortex, layer II: 26.6 + 7-1.6%) and moderate de-
mentia (NbM: 61.0+/−2.5, LC: 46.0+/−3.7%, entorhinal
cortex, layer II: 39.6+/−2.4%). At the most advanced
stages (AD severe dementia), average neurone loss
reached 83.3+/−1.53% in the NbM, 70.8+/−2.6% in the
LC and 57.2+/−2.6% in the entorhinal cortex, layer II.
Effect size of cell loss is largest in the basal nucleus, in
particular at more advanced stages of the disease
To make the effects of AD on neurone number compar-
able between the different regions, we calculated the ef-
fect size “d” of cell loss compared to the appropriate
control group (Figure 2). At preclinical AD, effect size
matched the criteria for a “small effect” (defined as 0.2 <
d < 0.3) [79,80]. It was somewhat larger in the NbM
(NbM: d = 0.32), compared to LC and entorhinal cortex,
layer II (LC: d = 0.22; entorhinal cortex, layer II: d = 0.25).
At prodromal AD/MCI, effect size matched the criteria of
a “large effect” (defined as d > 0.8) [79,80]. At this stage of
the disease, it was basically indistinguishable between thethree areas (NbM: d = 0.95; LC: d = 0.98; entorhinal cortex,
layer II: d = 1.06).
For the more advanced stages of moderate AD and
severe AD, effect size was clearly highest in the NbM
(d = 4.53 and d = 7.53), while its increase was somewhat
less pronounced for both the LC (d = 2.67 and d = 4.75)
and entorhinal cortex, layer II (d = 3.28 and d = 4.01)
(Figure 2).
Both cortical and subcortical neurone loss show a nearly
simultaneous onset
For a more direct comparison of cell loss in the three
different areas, both absolute neurone number and rela-
tive neurone loss in each of the regions were plotted
against those in the other two (Figure 3). Overall, there
was a very high degree of correlation of neurone loss in
each of the three areas with those in the other two areas
(correlation coefficient r ranging from 0.7794 to 0.8631;
p < 0.001).
Further, the intersections of the regression lines of cell
loss between different areas (right panel of Figure 3) are
all close to 0, indicating a nearly simultaneous onset of
cell loss in those areas.
Discussion
Most studies agree on the fact that both NbM and LC
show the greatest cell loss among subcortical areas in
AD. Still, only a few original reports, reviews or meta
analyses have directly compared the extent of cell loss in
the NbM and LC. To the best of our knowledge none of
them has compared neurone loss in these subcortical
areas to those in the entorhinal cortex within the same
subjects analyzing different stages of the disease.
Here, we report on neurone number in these brain
areas obtained by stereological techniques on 101 AD
patients and 19 healthy controls. Based on neuropsycho-
logical assessment and neuropathological examination,
AD patients were allocated to one of 5 stages reflecting
increasing disease progression.
Neurone counts in healthy controls
For the cohort of healthy controls, we determined neur-
one numbers in the NbM, LC and entorhinal cortex
layer II which are in very good agreement with previous
studies. For the NbM, we determined a neurone number
of 125,734 to 215,827, with a mean of 168,834+/−25,573.
Previous studies on normal elderly of about 80 years of
age reported a mean neurone count in the NbM of
167,200 to 178,400 with individual cell counts ranging
from 133,800 to 296,000 [9,26,73].
For the LC, we determined a neurone number of
13,371 to 22,712, with a mean of 17,487+/−2,736. This is
very close to previous estimates by unbiased stereologi-
cal techniques where cell counts varied between 15,731
Table 1 Synopsis of cases
Control Alzheimer’s disease
Preclinical AD Prodromal
AD/MCI
AD mild
dementia
AD moderate
dementia
AD severe
dementia
Number of cases 19 18 13 18 22 30
Gender: male/female 8/11 7/11 6/7 8/10 9/13 12/18
Age in years (+/-SD) 81.3 +/- 4.4 79.9 +/- 6.5 80.2 +/- 5.4 81.4 +/- 5.9 83.6 +/- 5.8 83.4 +/- 6.8
CDR
0 19 18
0.5 13
1 18
2 22
3 30
NFT stage*
0 19
1 18 6
2 7 6 4
3 12 18 30
Aß/amyloid plaque score*
0 19
1 18 5
2 8 4 2
3 14 20 30
CERAD*
0 19
1 18 4
2 9 5 2
3 13 20 30
ABC score*
Not 19
Low 18 7
Intermediate 6 6 4
High 12 18 30
Cause of death
Bronchopneumonia 5 15 10 12 16 25
Myocardial infarction 8
Congestive heart failure 1 1 1 2
Embolism of lung 3 3 1 2 1 2
Sepsis 1 2 3 1
Lung cancer 1 1
Pancreatic cancer 1
Breast cancer 1
Renal failure 1
Postmortem delay in h (+/-SD) 3.4 +/- 0.6 3.8 +/- 0.7 4.1 +/- 0.5 3.5 +/- 0.6 3.7 +/- 0.7 3.6 +/- 0.8
Fresh brain weight in gm (+/-SD) 1278 +/- 76 1258 +/- 51 1245 +/- 86 1212 +/- 56 1183 +/- 64 1150 +/- 103
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Table 1 Synopsis of cases (Continued)
Phospho-tau (mab AT8) positive pathology
Ncl basalis of Meynert 0 18 13 18 22 30
Locus coeruleus 0 18 13 18 22 30
Entorhinal cort. Layer II 0 18 13 18 22 30
Aß (mab 6E10) positive pathology
Ncl basalis of Meynert 0 0 8 18 22 30
Locus coeruleus 0 0 0 14 20 30
Entorhinal cort. Layer II 0 6 10 18 22 30
*according to [64].
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applying various different stereological and non-
stereological counting methods to the LC reported on
mean cell numbers between 11,500 and 19,100 with in-
dividual cell counts ranging from about 6,000-11,000 to
about 27,000-30,000 [28,30,33,37,81-86].
For the entorhinal cortex, layer II neurons, we deter-
mined numbers of 512,914 to 810,211 with mean valuesne
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Figure 1 Total number of neurons in the nucleus basalis of Meynert,
values for each brain together with mean values [+/−SD] for each groof 677,685+/−88,072. For comparison, previous stereo-
logical studies obtained mean numbers between 607,200
and 779,000 [87-90].
The range of percentage estimates of cell loss in
Alzheimer’s disease is large
Previous studies on the NbM, LC [22,28,31,33,35,37,41,
42,44,84,91] and entorhinal cortex layer II [87-90,92]ne
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locus coeruleus and entorhinal cortex layer II (data are individual
up [red]; Student’s t-test for comparison to controls).
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Figure 2 Comparison of effect size d for neurone loss in the nucleus
basalis of Meynert, locus coeruleus and entorhinal cortex layer II.
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to a great extent with reported figures of a few percent
up to 90% cell loss or even more. To some extent, this
variability can be explained by differences in the age and
disease stage of the patients which not always has been
controlled for as well as by different sampling and
counting protocols [90]. Still, even within each of the 5
stages of AD defined by neuropsychological and neuro-
pathological criteria we have analyzed here separately,
cell number shows a rather wide variability. Also, a
meta-analysis [93] reported on similar magnitudes in ef-
fect size when comparing stereological to non-
stereological studies on NbM and LC, suggesting that
the observed differences might reflect true biological
variability. In this meta-analysis, effect size ranged from
0.41 to 7.28 in the NbM and from 1.12 to 4.24 in the LC
[93]. In the present study, we obtained a comparable ef-
fect size between 0.95 and 7.53 for the NbM and be-
tween 0.98 and 4.75 for the LC, at stages of prodromal
AD and at AD with severe dementia, respectively.
In all three brain areas analyzed, neurone loss, still in-
significantly small by statistical means, became detect-
able already at preclinical AD. The simultaneous
presence of AT8 positive NFTs strongly suggests a
pathogenetic link towards fibrillary tau pathology. It
must remain open, however, at present to what extent
these degenerative changes represent localized disease-
specific pathology or might be attributed to an acceler-
ated aging process [94].Comparing cortical versus subcortical cell loss
A few studies described a somewhat greater neurone
loss in the NbM compared to LC. Jellinger et al. [95] re-
ported on a somewhat more severe involvement of the
NbM (15–90% neuron loss), compared to LC (4–88%
cell loss). Similarly, Moll et al. [40] described a much lar-
ger neurone loss in the NbM than in the LC. In a com-
prehensive meta-analysis, Lyness et al. [93] reported on
a somewhat larger effect size of neurone loss in the
NbM (effect size ranged from 0.41 to 7.28; mean d =
2.48, median d = 3.03; 33 studies) compared to the LC
(effect size ranged from 1.12 to 4.24; mean d = 2.28; me-
dian d = 2.62; 24 studies).
On the contrary, Geula and Mesulam [96] reported on
a 20–70% cell loss in the Ch4 area of the NbM com-
pared to a 40–80% cell loss in the LC. Mann et al.
[22,97], Ichimiya et al. [36] and Wilcock et al. [43] also
described a somewhat greater loss of neurons in the LC
than in the NbM, in particular in patients under 80 years
of age. Also, Zarow et al. [98] reported on a more pro-
nounced neurone loss in the LC compared to NbM.
Förstl et al. [99] clearly showed a relationship between
the history of depression and depletion of noradrenergic
neurons in the LC. In a prospective study, they observed
in a subgroup of AD patients with a history of depres-
sion a significantly lower neurone number in the LC and
slightly higher neuronal density in the NbM. Chan-Paly
and Asan [31] also described a loss (−55%) of LC neu-
rons in chronically depressed patients without dementia.
Still, Syed et al. [100] and Hoogendijk et al. [82] failed to
observe a link between depression and cell loss in the
LC in AD.
Our study clearly shows that at more advanced stages
of AD, i.e. AD with moderate or severe dementia, cell
loss is most pronounced in the NbM, while the layer II
entorhinal cortex neurons are least affected and the LC
shows an intermediate extent of cell loss. This is basic-
ally in agreement with the meta-analysis on NbM and
LC by Lyness et al. [93] where maximal effect sizes were
clearly higher for the NbM than for LC.
Still, the situation is much less conclusive for the very
early, i.e. preclinical stages of AD. The question where
the pathological process in the brain originates is still
controversial. Early studies in the eighties of the last cen-
tury had documented a contribution towards cortical
pathology of ascending cholinergic innervation arising in
the basal forebrain, suggesting a subcortical origin of
AD pathology [8,9,11]. Still, the currently prevailing con-
cept postulates an origin within the transentorhinal cor-
tex from where pathology spreads throughout the cortex
[1]. Recent findings on “pre-tangle” tau pathology in
subcortical projection nuclei, including LC and NbM in
individuals under 30 years of age [4,56], however, have
challenged this concept. Consequently, Braak et al. [4]
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Figure 3 Comparison of cell loss in the three different areas. Both total neurone number and relative neurone loss in each of the regions
were plotted against those in the other two. All relationships were significant at p < 0.001; r: coefficient of correlation according to Bravais-Pearson.
Arendt et al. Acta Neuropathologica Communications  (2015) 3:10 Page 8 of 11recently revised the NFT stages and included “pre-tangle
stages” in nonthalamic subcortical nuclei giving rise to
cortical innervation. In his survey on more than 2300
nonselected autopsy cases between 1 and 100 years of
age, he observed in a few cases a widely distributed sub-
cortical tau pathology, predominantly in the LC, in the
absence of cortical tau pathology. He, thus concluded on
an origin of tauopathy associated with sporadic AD in
the lower brainstem nuclei rather than in the transen-
torhinal region [4,101]. Still, there are arguments which
call into question an origin of pathology in the LC.
While the severity of tau pathology in the LC increases
with increasing NFT stages, there are still cases with
considerable entorhinal tau pathology and only minimalamounts of tau pathology seen in the LC: It has, thus,
been argued [102] that the LC becomes increasingly in-
volved during AD progression rather than being the site
initially affected.
Our findings show that both entorhinal cortex layer II
neurons and subcortical neurons in the NbM and LC
are reduced in number already at stages of prodromal
AD/MCI. First hints of cell loss, albeit still insignificantly
small, even occur already at preclinical stages, i.e. in the
complete absence of clinical symptoms. While through-
out all stages of the disease, some cases tend to show a
more severe involvement in one area than the other
(Figure 3, right panel), the overall pattern of cell loss ap-
peared to be fairly balanced between all three areas. We
Arendt et al. Acta Neuropathologica Communications  (2015) 3:10 Page 9 of 11thus failed to observe a systematic pattern which would
allow to conclude on an early site of lesion and a subse-
quent progression of pathology from one area to another.
To identify an initial site of degeneration if it exists, it
might be necessary to go even further back on the pre-
clinical time scale. Then, however, we run into the prob-
lem of how to recognize prospective AD subjects. It
might, thus, be too early to draw any conclusion on
whether AD pathology is of cortical or subcortical ori-
gin. Also, we need to consider that there might be more
than one way of speading of pathology from its site of
origin giving rise to different neuropathologically defined
subtypes of AD [103]. We even can not rule out at
present that degeneration occurs independently at sev-
eral sites in parallel.
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